Comparative Efficacy and Safety of Jintrolong and Other Long-Acting Growth Hormones for Growth Hormone Deficiency in East Asia: A Systematic Review and Network Meta-Analysis - PubMed
5 hours ago
- #Pediatric Endocrinology
- #Growth Hormone Deficiency
- #Network Meta-Analysis
- Jintrolong demonstrated superior efficacy in height velocity compared to daily GH and other LAGHs like pegpesen and somapacitan over 52 weeks.
- Significant improvements in change in height velocity and height standard deviation score were noted with Jintrolong versus daily GH.
- Safety profiles were similar across treatments, with no significant differences in adverse events or serious adverse events among Jintrolong, pegpesen, somapacitan, and daily GH.
- The systematic review and network meta-analysis included 5 studies focusing on pediatric growth hormone deficiency in East Asia.